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Abstract
Eosinophils and their mediators play a crucial role in various reactive states such as bacterial and viral infections, chronic
inflammatory disorders, and certain hematologic malignancies. Depending on the underlying pathology, molecular defect(s),
and the cytokine- and mediator-cascades involved, peripheral blood and tissue hypereosinophilia (HE) may develop and may
lead to organ dysfunction or even organ damage which usually leads to the diagnosis of a HE syndrome (HES). In some of these
patients, the etiology and impact of HE remain unclear. These patients are diagnosed with idiopathic HE. In other patients, HES is
diagnosed but the etiology remains unknown — these patients are classified as idiopathic HES. For patients with HES, early
therapeutic application of agents reducing eosinophil counts is usually effective in avoiding irreversible organ damage.
Therefore, it is important to systematically explore various diagnostic markers and to correctly identify the disease elicitors
and etiology. Depending on the presence and type of underlying disease, HES are classified into primary (clonal) HES, reactive
HES, and idiopathic HES. In most of these patients, effective therapies can be administered. The current article provides an
overview of the pathogenesis of eosinophil-associated disorders, with special emphasis on the molecular, immunological, and
clinical complexity of HE and HES. In addition, diagnostic criteria and the classification of eosinophil disorders are reviewed in
light of new developments in the field.
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Introduction
Eosinophil granulocytes are highly specialized hematopoietic
effector cells that play a crucial rule in host defense and tissue
remodeling. Eosinophils produce, store, and release an array
of biologically active substances, including cytotoxic proteins,
lipid mediators, chemotactic proteins (chemokines), and cyto-
kines [1–4]. Under various physiologic conditions and
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pathologies, eosinophils migrate into certain target organs,
and once activated, release their products in affected tissue
sites, thereby promoting local inflammation, tissue remodel-
ing, and sometimes tissue damage [1–9]. When peripheral
blood eosinophilia persists and exceeds 1500 cells/μL blood,
the term hypereosinophilia (HE) is appropriate [7–11]. In pa-
tients with HE, eosinophil-derived effector molecules can pro-
voke substantial alterations in the tissue microenvironments
[1–11]. In these cases, blood HE is usually accompanied by
tissue HE with local accumulations of eosinophils in affected
organs and deposition of eosinophil-derived cytotoxic and
tissue-remodeling proteins. In a subset of these patients, tissue
fibrosis and/or thrombosis with end organ damage develops,
resulting in the diagnosis of a HE syndrome (HES) [6–11].
The organ dysfunction induced by HE may be reversible or
irreversible, depending on the magnitude and duration of HE,
the underlying etiology, the presence of certain co-morbid-
ities, and response to therapy.
Blood and tissue HE can be observed not only in a variety
of reactive conditions, including allergic or inflammatory dis-
eases, auto-immune disorders, drug reactions, or infectious
diseases, but also in certain hematologic neoplasms, and
sometimes in patients with solid tumors (Table 1) [4, 6–19].
Persistent reactive HE is typically found in chronic (untreated)
helminth infections, other chronic infections, auto-immune
disease processes, other inflammatory reactions, and atopic
disorders (Table 1).
Hematopoietic malignancies that may present with marked
persistent HE encompass myeloproliferative neoplasms
(MPN-eo), certain forms of acute myeloid leukemia (AML-
eo), a small subset of patients with myelodysplastic syn-
dromes (MDS-eo), some MDS/MPN overlap disorders, cer-
tain lymphoproliferative disorders, including T cell Non-
Hodgkin’s lymphoma (NHL), and systemic mastocytosis
(SM-eo) (Table 1) [10–19]. These differential diagnoses must
be considered in patients with unexplained HE or HES, espe-
cially in the context of additional blood count abnormalities.
Therefore, it is standard to perform hematologic investiga-
tions, including bone marrow (BM) examinations and molec-
ular studies in such cases [13–19].
In patients suffering from a myeloid or stem cell–derived
hematopoietic neoplasm, eosinophils usually belong to the
neoplastic clone. In some of these patients, fusion genes in-
volving platelet-derived growth factor receptor (PDGFR)A,
PDGFRB, fibroblast growth factor receptor-1 (FGFR)-1,
Janus kinase-2 (JAK2), or other target genes are detected
(Table 1) [10, 11, 14–18]. This is important as PDGFR-
targeting tyrosine kinase inhibitors (TKI), like imatinib, are
effective in most PDGFR-rearranged malignancies, but not
in those with other molecular abnormalities, such as FGFR-
1 mutations [10, 11, 14–18].
During the past decades, our knowledge on eosinophils,
their products, eosinophil-rich neoplasms, and the
mechanisms underlying HE and HES-specific organ damage
has improved considerably [5–19]. Moreover, a number of
proposals for the classification of HE, HES, and related syn-
dromes have been published [7–11, 14–19]. The current arti-
cle provides an update and review of current concepts around
the diagnosis, classification, and management of HE, HES,
and related eosinophil-rich neoplasms.
Table 1 Conditions and disorders potentially associated with
hypereosinophilia (HE)
Reactive non-neoplastic conditions - secondary/reactive HE (HER)*
Chronic infections: viral, bacterial, fungal (e.g., aspergillosis)
Parasitosis (e.g., helminth infections)
Infestations (e.g., scabies)
Allergic or toxic drug reactions
Intoxication: toxic oil syndrome, others
Allergic disorders, including atopic dermatitis and allergic asthma
Acute and chronic graft-versus-host disease
Auto-immune disorders – rheumatologic disorders
Chronic inflammatory disorders, including EGID
Lymphoid variant of hypereosinophilic syndrome (HES-L)
Myeloid neoplasms and stem cell neoplasms with HE (neoplastic/primary
HE: HEN)**
Hematopoietic neoplasms with eosinophilia and rearranged PDGFRA
Hematopoietic neoplasms with eosinophilia and rearranged PDGFRB
Hematopoietic neoplasms with eosinophilia and rearranged FGFR1
Hematopoietic neoplasms with eosinophilia and PCM1-JAK2
Chronic eosinophilic leukemia – NOS
Chronic myeloid leukemia (CML-eo) – BCR-ABL1+
Myeloproliferative neoplasms (MPN) with HE (MPN-eo)
Systemic mastocytosis (SM) with HE (SM-eo)***
Myelodysplastic syndrome (MDS) with HE (MDS-eo)
MPN/MDS overlap syndromes with HE (MPN/MDS-eo; e.g.,
CMML-eo)
AML with inv(16) and eosinophilia (AML-M4-eo)
Neoplastic conditions with secondary/reactive HE (paraneoplastic HER)*
Solid tumors/cancers (lung, GI tract, others)
Langerhans cell histiocytosis
Hodgkin’s disease
B or T cell non-Hodgkin’s lymphoma
B or T cell leukemia
* In these patient groups, eosinophilia is usually caused by cytokines that
promote the growth and accumulation of eosinophils and their precursor
cells
** In these disorders, eosinophils are usually derived from the neoplastic
clone (from clonal stem cells)
*** Eosinophilia or even HE develop quite frequently in patients with
advanced systemic mastocytosis (SM), such as aggressive SM (ASM),
but may also occur in indolent SM (ISM) or smoldering SM (SSM)
EGI eosinophil-associated gastrointestinal disorders, NOS not otherwise
specified, CML chronic myeloid leukemia, MDS myelodysplastic syn-
drome, MPN myeloproliferative neoplasm, CMML chronic




migration, and activation of eosinophils
Eosinophils derive from pluripotent and lineage-related
hematopoietic precursor cells [4, 20–25]. Bi-lineage-
restricted progenitor cells giving rise to eosinophils and
basophils (CFU-eo/ba) are commonly detected in the BM
and peripheral blood of healthy individuals, patients with
reactive (inflammatory) disorders, and those with myelo-
proliferative neoplasms [20–25]. The development of eo-
sinophils from their multipotent and lineage-specific pre-
cursor cells is coordinated by a network of transcription
factors, growth-promoting cytokines, and growth-
inhibitory mediators. Growth factors for eosinophil pre-
cursor cells include interleukin (IL)-5, granulocyte/
macrophage colony-stimulating factor (GM-CSF), and
IL-3 (Table 2) [26–28]. These growth-modulating cyto-
kines are primarily synthesized and secreted by
(activated) T cells, mast cells, and stromal cells.
Receptors for these cytokines are expressed on
multipotent myeloid precursor cells, eosinophil-
committed progenitors, immature eosinophils (all mor-
phological stages), and mature eosinophils [29–31].
Correspondingly, these growth factors mediate not only
the proliferation of eosinophil precursor cells but also mi-
gration, adhesion, survival, and activation of mature eo-
sinophils (Table 2) [32–34]. Apart from the classical eo-
sinophilic growth regulators, other cytokines, such as IL-
13, platelet-derived growth factor (PDGF), or nerve
growth factor (NGF), may also contribute to the differen-
tiation and maturation of normal and neoplastic eosino-
phils (Table 2) [35–37]. In addition, a number of
chemokines, such as stroma cell–derived factor-1 (SDF-
1 = CXCL12), CCL5 (RANTES), CCL11 (eotaxin-1),
CCL24 (eotaxin-2), CCL26 (eotaxin-3), or platelet-
activating factor (PAF), can induce eosinophil migration,
activation, and/or chemotaxis (Table 2) [38–48]. The most
potent chemotactic molecule for neoplastic eosinophils
may be SDF-1 (Fig. 1) [48].
The development, survival, and function of eosinophils are
also controlled by diverse inhibitory cytokines, their receptors,
and other inhibitory receptors and “negative-regulators”
[49–55]. Among cytokines, transforming growth factor-beta
(TGF-beta), interferon-alpha (IFN-alpha), and IFN-gamma
have been described to inhibit cytokine-induced differentia-
tion of human eosinophils from their progenitor cells (Table 2)
[51–54]. Moreover, certain cytokines, like IFN-gamma, can
block cytokine-mediated migration of eosinophils [56]. All
these cytokine-induced effects on eosinophils and their pre-
cursor cells are considered to be mediated via specific cell
surface receptors. Eosinophils also display receptors for
glucocorticosteroids which inhibit growth, activation, and sur-
vival of these cells [57, 58].
Phenotype and target expression profile
of eosinophils in health and disease
Eosinophils express a unique composition of cell surface re-
ceptors relevant to adhesion, homing, and migration in tissues
[4, 5, 59–69]. Some of these receptors contribute to the trans-
migration of eosinophils across endothelial monolayers and
thus to the homing of eosinophils and their precursor cells in
tissues, which is critical for the development of tissue HE
found in patients with HE-related organ damage.
Eosinophils display the C3bi receptor (CD11b/CD18), leuko-
cyte function antigen-1 (LFA-1 = CD11a/CD18), L-selectin,
E- and P-selectin ligands, low levels of sialyl Lewis x, and
intercellular adhesion molecules (ICAM) [59–69]. Moreover,
eosinophils display leukosialin (CD43) and the leukocyte-
invasion receptor CD44.Whereas selectins and their receptors
are considered to mediate eosinophil rolling and tethering on
vascular cells, integrins and other receptors cause firm binding
of eosinophils to endothelial cells prior to transmigration into
tissues. Various cytokines and peptides may promote the ex-
pression and/or function of adhesion antigens on eosinophils.
By contrast, glucocorticosteroids and some of the anti-
inflammatory cytokines may block expression of adhesion
receptors on eosinophils and thus adhesion of eosinophils
and their transmigration into tissues [70, 71]. On the other
hand, glucocorticosteroids may even upregulate expression
of certain homing receptors, like CXCR4 (receptor for SDF-
1), on eosinophils [72].
Eosinophils also have on their surface several biologically
relevant, activation-linked cell surface membrane antigens,
including complement receptors, toll-like receptors, Fc recep-
tors, gangliosides, glycoproteins, and Siglec molecules, such
as Siglec-8 [49, 73–78]. In addition, activated eosinophils and
neoplastic eosinophils can display CD25 (Table 2) [79].
Among all these receptors, Siglec-8 appears to be a rather
specific surface molecule that is expressed on eosinophils
and their progenitor cells but not to any significant degree
on other blood leukocytes [49, 78].
Finally, eosinophils display a number of cell surface recep-
tors for certain viruses and related antigens, including the co-
rona virus receptors CD13 and CD147, the measles virus re-
ceptor CD46, and the Echo-/Coxackie virus receptor CD55
(DAF) (Table 3 and Fig. 2) [59]. Once activated by cytokines,
such as IFN-gamma or tumor necrosis factor alpha (TNF-al-
pha), eosinophils may display additional virus receptors, such
as the rhinovirus receptor CD54 (ICAM-1) [80]. Whether eo-
sinophils can serve as a reservoir for certain viruses or as
effector cells of tissue damage following virus infection, such
as SARS-CoV-2 infection, remains unknown. It is worth not-
ing in this regard that tissue inflammation and tissue damage
(lung) induced by certain corona viruses are sometimes resem-
bling features of HES. On the other hand, however, HE is
usually not seen in patients with SARS-CoV-2 infections.
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Eosinophil-derived molecules and their
impact in HE-induced organ damage
Eosinophils produce an array of proinflammatory mediators
and cytokines, including interleukins, chemokines, and other
compounds [1–5, 81–85]. Several of these molecules, such as
the chemokines, can recruit and/or activate leukocytes in af-
fected organ sites. Other molecules contribute to the mobili-
zation and activation of local microenvironmental cells, such
as fibroblasts or endothelial cells, and thereby trigger tissue
fibrosis, angiogenesis, and tissue remodeling [81–85]. In ad-
dition, eosinophils generate lipid-based mediators, including
cysteinyl leukotrienes and prostaglandins which contribute to
tissue inflammation and organ dysfunction (Table 4) [81–85].
Eosinophils can synthesize and release a number of specif-
ic cytotoxic effector proteins, including eosinophil cationic
protein (ECP), eosinophil major basic proteins (MBP1 and
MBP2), eosinophil peroxidase (EPO), and eosinophil-
derived neurotoxin (EDN) (Table 4) [86, 87]. These com-
pounds and other molecules, such as the eosinophil-derived
Table 2 Stimuli and their receptors that alter various human eosinophil functions
Stimulus The effects on eosinophils and/or their precursor cells Receptor/s (R)
Differentiation-inducing
IL-3 Differentiation, survival, adhesion, migration, activation, priming IL-3R = CD123+CD131
IL-5 Differentiation, survival, adhesion migration, activation, priming IL-5R = CD125+CD131
GM-CSF Differentiation, survival, adhesion, migration, activation, priming GM-CSFR = CD116+CD131
Growth- or survival-promoting
PDGF Survival*, activation? PDGFRA/B
FGF Survival*, activation? FGFR1
IL-25 Survival, activation IL-25R
IL-27 Survival, activation IL-27R
Inhibitory
TGFß1 Inhibitory (growth, activation) TGFß1R
TGFß2 Inhibitory (growth, activation) TGFß2R
IFN-alpha Inhibitory (growth) IFN-alpha-R
IFN-gamma Inhibitory (growth, migration) IFN-gamma-R
IL-10 Inhibitory (activation, survival) IL-10R
IL-12 Inhibitory (activation) IL-12R
Activating and/or migration-inducing
C3a, C5a Chemotaxis, activation C3aR, C5aR
PAF Chemotaxis, activation PAF-R
SDF-1 (CXCL12) Chemotaxis CXCR4
RANTES (CCL5) Chemotaxis, activation CCR3
MCP-3 (CCL7) Chemotaxis, activation CCR3
MCP-4 (CCL13) Chemotaxis, activation CCR3
Eotaxin (CCL11) Chemotaxis, activation CCR3
Eotaxin-2 (CCL24) Chemotaxis, activation CCR3
Eotaxin-3 (CCL26) Chemotaxis, activation CCR3
IL-2 Activation, PRIMING IL-2RA/CD25
IL-4 Priming for chemotaxins IL-4R/CD124
IL-13 Activation? IL-13R
IL-16 Activation, priming CD4,CD9(?),CCR3
IL-33 Activation, adhesion, migration IL-33R/ST2
VEGF Chemotaxis, activation VEGFR-1/FLT-1
Angiopoietin-1 Chemotaxis, activation? Tie-2/TEK
* In hematologic malignancies with HE where oncogenic mutant forms of PDGFR or FGFR are expressed by neoplastic (progenitor) cells, the
differentiation of eosinophils is considered to be triggered primarily by these oncogenic mutant forms of PDGFR/FGFR
PDGF platelet-derived growth factor, FGF fibroblast growth factor, PAF platelet-activating factor, IL interleukin, GM-CSF granulocyte/macrophage
colony-stimulating factor, TGF transforming growth factor, IFN interferon, CCL chemokine ligand, CCR chemokine receptor,MCP monocyte chemo-
tactic protein, VEGF vascular endothelial growth factor
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extracellular DNA traps, contribute to microbe killing and
thus innate immune host defense [86–88]. These DNA traps
produced by eosinophils may also contribute to thrombophilia
that is often associated with HE. Eosinophils also produce and
release Charcot-Leyden crystals (CLC) which consist of the
eosinophil granule protein Galectin-10 and may contribute to
type 2 immunity and tissue inflammation [89]. Finally, eosin-
ophils produce a number of repair molecules that may be
involved in tissue homeostasis after an inflammatory or toxic
reaction in local tissue sites. Likewise, eosinophil-derived
molecules may counteract or degrade vasoactive molecules
such as histamine (eosinophil-derived histaminase).
Concerning HE-related organ damage, little is known
about the exact role each of the eosinophil-derived substances
play in various disease contexts. It is generally appreciated
that eosinophil-derived chemokines, cytokines, and mediators
contribute to leukocyte recruitment, tissue inflammation,
thrombosis, fibrosis, and subsequent tissue damage
(Table 4). Eosinophil products known to mediate fibrosis
and thrombosis by affecting endothelial cell and/or platelet
function include among others, DNA traps, plasminogen ac-
tivator inhibitors, and toxic proteins [87–94].
These eosinophil-derived mediators and cytokines may all
act together to cause thrombophilia, tissue fibrosis, and thus
organ dysfunction or even tissue damage in patients with HE/
HES in various contexts and pathologies.
Definition and classification of HE and HES
Eosinophilia can be divided into relative and absolute eosin-
ophilia, slowly progressing versus suddenly occurring eosin-
ophilia, transient versus persistent eosinophilia, and mild (up
to 1500/μL) versus marked eosinophilia (>1500/μL). When
eosinophilia is marked and persists for several months, the
term blood HE is appropriate [7–11, 95]. Blood HE may or
may not be accompanied by tissue HE in various organ sys-
tems. The term tissue HE is less well defined than the term
blood HE. In general, tissue HE is characterized by a marked
increase in eosinophils and/or a substantial deposition of
eosinophil-derived proteins, like MBP, in tissue sections in
affected organs [6–11, 91, 96, 97]. In patients with chronic
tissue HE, eosinophils usually undergo cell death and disap-
pear in local sites after activation and release of their proteins,
so that the predominant histological finding of tissue HE may
be deposition of MBP and other eosinophil-derived proteins
without eosinophil accumulations [91, 96].
Based on the underlying etiology, several variants of HE
have been defined [10, 11]: a very rare hereditary (familial)
variant (HEF), HE of unknown significance (HEUS) where the
cause and clinical impact of HE remain unknown, primary
(neoplastic) HE (HEN) where clonal (neoplastic) eosinophils
are detected, and secondary, reactive HE (HER) where normal
(activated, non-neoplastic) eosinophils expand in a reactive
(often inflammatory) process (Table 5) [10, 11]. In rare cases,
HER is induced by a neoplastic process such as a lymphoma, a
gastrointestinal tumor, or a lung carcinoma. In most patients
with HER, HE may be induced by eosinotropic cytokines, like
IL-5.
Patients with unexplained HE may be asymptomatic for
several months or even years. As mentioned, these patients
are classified as HEUS (Table 5) [10, 11]. In these patients, no
underlying (neoplastic or non-neoplastic) disease and no HE-
induced organ damage are detected. Several of these patients
may develop signs and symptoms of eosinophil-mediated or-
gan damage during follow-up. When HE leads to organ dam-
age in such patients, the final diagnosis is “hypereosinophilic
syndrome” (HES) [10, 11].
Like HE, HES is also divided into distinct variants based
on underlying etiologies: idiopathic HES (unknown etiology:
HESUS), primary (neoplastic) HES with an underlying clonal
myeloid or stem cell disorder (HESN), and secondary
(reactive) HES in which a related non-neoplastic or
paraneoplastic condition is detected and is responsible for
the expansion of (activated) eosinophils (HESR) (Table 6)
[10, 11].
A number of special variants of HES have also been de-
scribed. One is the so-called lymphoid variant of HES (HES-
L) [98–101]. Although no solid diagnostic criteria are avail-
able, HES-L exhibits several features of (and may therefore be
regarded as) reactive HES (HESR). Typically, T lymphocytes
Fig. 1 The effects of various cytokines on migration of neoplastic
eosinophils. The eosinophil cell line EOL-1 carrying FIP1L1-PDGFRA
was loaded in the upper chambers of a Boyden-type double-chamber
system. The lower chambers were supplemented with control medium
or medium containing recombinant human SDF-1ɑ (25 ng/ml), IL-5 (100
ng/ml), eotaxin (500 ng/ml), FGF-1 (100 ng/ml), FGF-2 (100 ng/ml),
PDGF-AA (100 ng/ml), or PDGF-BB (100 ng/ml). After 4 h (5% CO2,
37 °C), the numbers of viable migrated cells collected in the lower
chambers were measured by flow cytometry. Results are expressed as
percent of all viable cells (100% input) and represent the mean ± S.D.
of 3 independent experiments. Asterisk (*), p < 0.05 compared tomedium
control. Abbreviations: SDF-1, stroma cell–derived factor; IL-5,
interleukin-5; FGF, fibroblast growth factor; PDGF, platelet-derived
growth factor
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in these patients exhibit an abnormal phenotype (such as
CD3−/CD4+). In most cases, a clonal T cell receptor rear-
rangement is found. The clinical course of patients with
HES-L is often indolent without signs of progression.
However, some of the patients may progress to an overt T cell
lymphoma.
A number of organ systems may be affected in HES, in-
cluding the heart, lung, skin, gastrointestinal tract, and the
central nervous system [6–11, 102–104]. A particularly dev-
astating manifestation of HES is the thromboembolic state
which may include stroke, intracavitary thrombi in the heart,
and vascular (arterial and/or venous) thrombosis. In addition,
endomyocardial fibrosis, chronic tissue inflammation, and ul-
cerations in the skin are often seen in patients with HES [6, 10,
11, 102–104]. Such HES-associated organ damage may de-
velop in all variants of HES, independent of the underlying
etiology.
Endomyocardial fibrosis and thrombus formation as well
as cardiac arrest are also seen in patients with eosinophil-rich
neoplasms carrying the FIP1L1-PDGFRA fusion gene or
other PDGFR variants. Most of these patients respond well
to imatinib and early treatment with this drug may prevent
irreversible organ damage in these patients [105–108].
Therefore, it is of considerable importance to perform diag-
nostic investigations, including molecular studies, as early as
possible and to start treatment with imatinib before irrevers-
ible organ damage develops.
Diagnostic evaluations, staging,
and diagnostic algorithms
Initial investigations in patients with HE include a detailed
case history, especially travel histories, food, and toxin expo-
sures, and certain infections and infestations. In the case of a
suspected helminth infection, stool examinations and serology
tests should be performed [8–11, 13]. In addition, bacterial
and viral infections must be excluded or diagnosed by appro-
priate serology and molecular assessments [8–11, 13].
Table 3 Cell surface receptors for
viruses expressed on human
eosinophils and EOL-1 cells
Expressed on
Antigen-receptor CD Virus Eosinophils EOL-1
Corona virus receptors
Aminopeptidase-N 13 Corona virus + +
DPPIV 26 Corona virus − +
Basigin 147 Corona virus + +
Other virus receptors
T4 antigen 04 HIV − −
Complement R2 (CR2) 21 EBV − −
Membrane co-factor protein 46 Measles virus + +
VLA-2 49b Echo virus − −
VLA-3 49c Herpes virus-8 − −
VLA-6 49f Papilloma viruses? + +
ICAM-1 54 Rhino virus +/−* +
Decay accelerating factor 55 Echo virus-70 + +/−
MACIF 59 African swine virus + +
Tetraspan-28 81 HCV + +
Nectin-1 (PVRL1) 111 Env gD of herpes virus +/− +/−
Nectin-2 (PVRL2) 112 Env gD of herpes virus + +
PVR 155 Polio virus +/− +
CXCR4 184 HIV + +
CCR5 195 HIV − n.t.
JAM-A 321 Reo virus + +
Results refer to data published in the literature or data obtained in our laboratories by flow cytometry. In these
experiments, expression of virus receptors on Siglec-8-positive blood eosinophils and the eosinophilic cell line
EOL-1 was examined by monoclonal antibodies and multi-color flow cytometry
* Cytokine-activated eosinophils may express the cell surface antigen ICAM-1 (CD54)
DPPIV dipeptidyl-peptidase IV, HIV human immunodeficiency virus, EBV Epstein Barr virus, VLA very late
antigen, ICAM intercellular adhesion molecule, HCV hepatitis C virus, n.t. not tested
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When no causative infection, drug, or toxin can be identi-
fied, the patient is examined for the presence of allergic
(atopic) diseases, chronic inflammatory diseases, blood cell
disorders, and other neoplastic conditions [8–19, 109, 110].
It is also worth noting that HE may be caused by more than
one trigger or underlying disease. Therefore, diagnostic eval-
uations in HE should always encompass all major etiologies.
In all patients with HE, detailed laboratory examinations
are performed, including blood counts with differential
counts, serum chemistry including a basal serum tryptase lev-
el, inflammation markers (including fibrinogen and CRP), au-
toantibodies, serum IgE, and vitamin B12 [10, 11, 109, 110].
In those with a suspected hematologic disease, molecular
screen parameters are applied, including assays detecting
PDGFR-related fusion gene products, such as FIP1L1-
PDGFRA, KIT D816V, JAK2 V617F, BCR-ABL1, and clonal
T cell receptor rearrangement [10, 11, 13–18]. When these
parameters disclose negative results, next generation sequenc-
ing (NGS) and BM studies should be considered. BM inves-
tigations are also performed when these screens show a posi-
tive test-result or other signs and symptoms suggest that the
patient is suffering from a hematopoietic neoplasm. In patients
with suspected eosinophilic leukemia or other myeloid neo-
plasms, the underlying disease is diagnosed based on WHO
criteria [10, 11, 13–19]. Investigations in these patients in-
clude morphologic studies of eosinophils and other cell types
on good-quality BM and blood smears (stained with Wright-
Giemsa) and a BM core biopsy with histology and immuno-
histochemistry to define the number, distribution, and pheno-
type of myeloid (precursor) cells, mast cells, megakaryocytes,
and other BM cells, and to document or exclude BM fibrosis
and myelodysplasia. Additional examinations include a de-
tailed flow cytometry analyses, conventional cytogenetics,




EOL-1 PB EosinophilsFig. 2 Expression of corona virusreceptors on human eosinophils.
EOL-1 cells (left panels) and
normal peripheral blood (PB)
eosinophils were stained with PE-
conjugated antibodies against
three corona virus receptors,
namely CD13 (aminopeptidase-
N: clone WM15), CD26 (DPPIV:
clone M-A261), and CD147
(basigin: clone HIM-6). Antibody
reactivity (orange histograms)
was analyzed by flow cytometry.
The isotype-matched control
antibody is also shown (black
open histograms). Abbreviations:




Table 4 Eosinophil products and their potential impact in the etiology of HE and HES
Eosinophil product Effects potentially relevant to HE-related organ damage = HES*
Cytokines/interleukins
GM-CSF Leukocyte/eosinophil activation
IL-1 Endothelial cell activation, inflammation
IL-2 Activation of T lymphocytes
IL-3 Eosinophil accumulation and activation
IL-4 B cell maturation and mast cell development
IL-5 Eosinophil accumulation and activation
IL-6 Eosinophil accumulation and activation
IL-8 Leukocyte recruitment/activation
IL-13 Bronchial hyperreactivity, mucus production, B cell maturation
TGF-alpha Fibrosis, growth inhibition
TGF-beta Fibrosis, growth inhibition
TNF-alpha Endothelial activation, inflammation, cachexia
OSM Fibrosis, angiogenesis**
Chemokine ligands
Eotaxin (CCL11) Further eosinophil recruitment
MIP-1-alpha (CCL3) Leukocyte recruitment & activation
RANTES (CCL5) Leukocyte recruitment & activation
Eosinophil-derived basic proteins
Eosinophil cationic protein (ECP) Direct toxic effects, mucus secretion, fibrosis
Eosinophil-derived neurotoxin (EDN) Direct toxic effects, TLR2 ligand effects, RNase
Eosinophil peroxidase (EPO) Direct toxic effects, leukocyte activation
Major basic protein (MBP) Direct toxic effects, leukocyte activation
Toxic and immunoregulatory enzymes
Acid phosphatase Direct toxic effect
Arylsulphatase B Lysosomal hydrolase
Catalase Direct toxic effects
Hexosaminidase Direct toxic effects
Histaminase Histamine degradation
Lysophospholipase Direct toxic effects
Nonspecific esterases Direct toxic effects
Phospholipase D LFA-dependent adhesion
Membrane-derived lipid-compounds
LTC4 Mucus secretion
PAF Bronchoconstriction, edema formation
PGE1 & PGE2 Diverse effects on platelets, endothelial cells, fibroblasts and other tissue cells
15–HETE Diverse effects on blood and tissue cells
TXB2 Platelet aggregation
HE-Related DNA Traps Direct toxic effect & prothrombotic effects
Fibrinolysis blocker
PAI-2 Anti-fibrinolytic and prothrombotic effects
* The direct toxic effects of the eosinophil-derived mediators, proteins and enzymes are often directed against certain microbes such as bacteria
(antimicrobial effects) but may also be directed against various physiologic cells, especially when the number of eosinophils and the concentrations
of these eosinophil-derived compounds increase in tissues, which may lead to tissue damage and thereby HES
**Neoplastic eosinophils triggered by various PDGFR mutant forms express and release increased amounts of OSM, certain chemokines, and other
microenvironmental cell regulators compared to normal blood eosinophils
HE hypereosinophilia, IL Interleukin, GM-CSF granulocyte/macrophage colony-stimulating factor, TGF transforming growth factor, TNF tumor
necrosis factor, OSM oncostatin M, PAF platelet-activating factor, PGE prostaglandin E, TX thromboxane, PAI-2 plasminogen activator inhibitor-2
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studies, including PCR and NGS [10, 11, 16–18]. PCR and
FISH are required to detect certain fusion gene variants, such
as FIP1L1-PDGFRA and the related CHIC2 deletion (by
FISH) [10, 11, 16–18]. In patients with suspected lymphoid
HES, a detailed flow cytometric analysis of lymphocytes
should be performed, with the aim to exclude or identify ab-
errant populations, such as CD3−/CD4+ T cells which are
often detected in the lymphoid variant of HES = HES-L
[8–11, 98–101].
In all patients with suspected HES, HE-induced organ dam-
age should be documented by appropriate staging investiga-
tions, including physical examinationwith a detailed inspection
of the skin, cardiologic assessments, measurements of serum
troponins and pro B-type natriuretic peptide (proPNB), an elec-
trocardiogram and echocardiogram, assessment of pulmonary
function, chest X-ray, abdominal imaging, computed tomogra-
phy, cardiac MRT and biopsy, and gastrointestinal examina-
tions with endoscopic biopsy studies [6–13, 109, 110].
Table 5 Classification of hypereosinophilia (HE)
Variant of HE Abbreviation Features
Hereditary (familial) HE HEFA Familial clustering, no evidence of a hereditary immunodeficiency,
no evidence of a reactive or neoplastic underlying disease, and no
signs or symptoms indicative of HES
HE of unknown significance HEUS No known underlying etiology of HE, no positive family history, no
evidence of a reactive or neoplastic condition or disorder underlying HE
Secondary (reactive) HE HER Underlying reactive condition or disease that explains HE, no evidence for
a clonal bone marrow disease that explains HE*
Primary (clonal/neoplastic) HE HEN Underlying stem cell, myeloid, or eosinophil neoplasm inducing HE*
* In primary, neoplastic HE (HEN), eosinophils are considered to be clonal cells derived from neoplastic stem cells, whereas in reactive HE (HER),
eosinophils are considered to be reactive (non-clonal) cells triggered by eosinophiliopoietic cytokines such as interleukin-5
HE hypereosinophilia, HES hypereosinophilic syndrome
Table 6 Classification of hypereosinophilic syndromes (HES) and related disorders
Variant Typical features
Idiopathic HES No underlying cause of HE, no evidence of a reactive or neoplastic condition/disorder
underlying HE, and end organ damage attributable to HE
Primary (neoplastic ) HES (HESN) Underlying stem cell, myeloid, or eosinophil neoplasm classified according to WHO and
end organ damage attributable to HE. Eosinophils are considered (or shown) to be
neoplastic (clonal) cells*; HESN
Secondary (reactive) HES(HESR) Underlying condition/disease where eosinophils are considered non-clonal cells, and HE is
considered to be cytokine-driven (HESR), and end organ damage attributable to HE
Special variants/syndromes
Lymphoid variant of HES (HES-L)** Abnormal clonal T cells often detected, HES-related organ damage found, but angioedema
and elevated IgM usually absent
Episodic angioedema and eosinophilia (Gleich’s
syndrome)
Abnormal clonal T cells usually detected, angioedema, and elevated polyclonal IgM
Eosinophilic granulomatosis with polyangiitis =
(EGPA) = Churg-Strauss syndrome
Polyangiitis, necrotizing angiitis, asthma, lung infiltrates; in a subset of patients, ANCA can
sometimes be detected (ANCA+ form of EGPA)
Eosinophilia myalgia syndrome (EMS) Myalgia, muscle weakness, cramping, skin rash, dyspnea, fatigue
Omenn syndrome Autosomal recessive disease with hypomorphic missense mutations in immunologically
relevant genes, like RAG1 or RAG2, severe combined immunodeficiency with recurrent
infections, auto-reactive T cells, skin rash, erythroderma, splenomegaly,
lymphadenopathy, GvHD-like symptomatology
Hyper-IgE syndrome Hereditary immunodeficiency syndrome, elevated serum IgE, recurrent bacterial infections,
often with eczema and facial anomalies. Autosomal dominant variant: STAT3 mutations.
Autosomal recessive variant: DOCK8 mutations
* Clonality of eosinophils is often difficult to demonstrate or is not examined. However, if a myeloid or stem cell neoplasm known to present typically
with clonal HE, is present, or a typical molecular defect is demonstrable (e.g., PDGFR or FGFR mutations or BCR-ABL1), eosinophilia should be
considered clonal
** The lymphoid variant of HES is regarded a special form of secondary HES, although its exact nature and pathogenesis remain controversial




Once HE has been diagnosed, its etiology must be determined
and the question as to whether (or not) the patient is suffering
from HES (HE-induced organ damage) has to be clarified. In
most patients with HE, an underlying reactive condition or
neoplastic disease will be diagnosed, leading to the provision-
al diagnosis HER [10, 11]. In rare cases, a familiar variant of
HE is identified (Table 5). When no underlying disease, no
positive family history, no organ damage, and no other related
disease or syndrome associated with HE is detected, the pro-
visional diagnosis HEUS is appropriate [11].
A number of reactive conditions and underlying diseases
can produce HE (Table 1). Specifically, reactive HE (HER)
may develop not only in patients with an underlying parasitic,
bacterial, fungal, or viral infection but also in patients with
IgE-dependent or IgE-independent allergies and patients with
chronic inflammatory (auto-immune-mediated) disorders. In a
subset of these patients, a reactive HES (=HESR) is diagnosed.
In addition, HER may be identified in cancer patients, for
example in adenocarcinomas developing in the lung, cervix,
or the gastrointestinal (GI). There are also a few hematological
malignancies where eosinophilia is typically reactive in na-
ture, such as in Hodgkin’s lymphoma, T cell lymphomas, or
B cell acute lymphoblastic leukemia.
Myeloid neoplasms that typically present with clonal/
neoplastic HE (HEN) include Ph
+ CML, certain variants of
AML, and advanced SM (Table 1) [10, 11, 14–19].
Moreover, marked eosinophilia (and sometimes HE) may de-
velop in MDS, MPN, and MDS/MPN overlap neoplasms,
including chronic myelomonocytic leukemia (CMML).
These neoplasms should be diagnosed and classified using
WHO criteria [10, 11, 14–19]. Based on these criteria, hema-
topoietic neoplasms producing eosinophilia are initially clas-
sified according to the presence or absence of certain gene
variants, including abnormalities (mutant forms) of
PDGFRA, PDGFRB, or FGFR1, or the PCM1-JAK2 fusion
gene. When one of these genetic lesions is detected, the final
histopathological and hematological diagnoses still need to be
determined, since the underlying disease may be an acute
leukemia, an eosinophil-rich chronic leukemia, a MPN, or a
CMML [10, 11, 14–19]. Additional gene variants that may be
detected in patients with myeloid neoplasms and eosinophilia
include, among others, ETV6-ABL1, STAT5B N642H, and
JAK2ex13InDel. Both the type of molecular lesion and the
type of underlying disease have prognostic and therapeutic
implications. For example, most (chronic) hematopoietic neo-
plasms exhibiting the FIP1L1-PDGFRA fusion protein are
responsive to treatment with imatinib [105–108] whereas this
is not the case in patients with a FGFR1-mutated malignancy.
Indeed the prognosis changes when the FIP1L1-PDGFRA+
neoplasm turns out to be an acute leukemia.
Another important aspect is lineage involvement. For in-
stance, in patients with PDGFR variants, lymphoid involve-
ment is rarely seen, while patients with FGFR1-mutated neo-
plasms with concomitant HE may present with a stem cell
malignancy exhibiting lymphoid and myeloid involvement.
The WHO classification also includes the category “chronic
eosinophilic leukemia — not otherwise specified” (CEL
NOS) [14–18]. However, there are patients who present with
a more acute form of an eosinophil leukemia. Therefore, the
international cooperative study group on eosinophil disorders
(ICOG-EO) proposed to delineate between acute eosinophilic
leukemia (AEL) and chronic eosinophilic leukemia (CEL),
based on the percentage of blast cells [11].
In patients with HE in whom eosinophils are ≥30% and
blast cells are ≥20% of all nucleated (BM or blood) leuko-
cytes, the diagnosis is AEL [11]. In patients with HE in whom
eosinophils are ≥30% and blast cells are <20% of all nucleated
(BM or blood) leukocytes, the diagnosis is CEL [11].
Finally, there are a number of organ-specific disorders and
systemic syndromes defined by HE and HES or HES-like
pathologies. Although these syndromes have been separated
from the classical variants of HES, the clinical presentations
and courses often resemble HES [11]. Organ-specific disor-
ders include eosinophil inflammatory states, such as eosino-
philic esophagitis, eosinophilic gastritis, eosinophil
duodenitis, eosinophil colitis, eosinophilic pneumonia, and
eosinophilic hepatitis. In most of these reactive conditions,
the disease is triggered by certain eosinopoietic cytokines such
as IL-3, IL-5, IL-13, or GM-CSF, and at least for eosinophilic
esophagitis/gastritis, ingestion of certain foods can be a crucial
trigger. Systemic (multi-organ) syndromes include, among
others, episodic angioedema and eosinophilia (Gleich’s syn-
drome), eosinophilic granulomatosis with polyangiitis
(EGPA; formerly Churg-Strauss syndrome = CSS), eosino-
philia myalgia syndrome (EMS), Omenn syndrome, and the
Hyper-IgE syndrome.
A detailed description of all these pathologies and syn-
dromes is beyond the scope of this article. We refer the reader
to the available literature. Gleich’s syndrome is defined by
recurrent angioedema, peripheral blood HE, and elevated
polyclonal IgM [111–113]. In several of these patients, phe-
notypically abnormal (activated) T cells (CD4+ T cells with
decreased CD3 expression) can be documented [101, 113].
Based on this notion, the Gleich’s syndrome is also regarded
as special form or manifestation of HES-L. Typical features of
EGPA/CSS are asthma, a necrotizing vasculitis, and eosino-
philia [114–116]. In a subset of these patients, anti-neutrophil
cytoplasmic antibodies (ANCA) are detected [114–116].
EMS is characterized by myalgia, neurologic symptoms, and
skin exanthema. Epidemic cases of EMS have been reported.
In these patients, exposure to L-tryptophan has been described
[117–119]. Therefore, the condition has also been termed tox-
ic oil syndrome [117–119]. Both Omenn syndrome and the
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Hyper-IgE syndrome are rare inherited immunodeficiency
disorders accompanied by eosinophilia.
Contemporary management of patients
with HE-related disorders
For patients with HEUS and HEF with a stable (silent) clinical
course, a wait-and-watch strategy may be chosen, provided
that no signs or symptoms indicative of organ dysfunction or
organ damage develop [10, 11]. In fact, both HEUS and HEF
are provisional diagnoses and in both instances, a hematologic
disease or reactive disease with or without organ damage may
develop in the follow-up [8–14].
The reactive form of HE (HER) is best managed by treating
and (if possible) eradicating the underlying disease or pathol-
ogy [8–11, 105–109, 120–124]. When eradication is not pos-
sible, symptomatic therapy may be sufficient to control prob-
lems related to eosinophil activation and HE in these patients.
In many of these patients, organ damage (=HESR) can be
prevented by administration of glucocorticosteroids and/or
other anti-inflammatory drugs [8–11, 109, 120–124]. In pa-
tients with severe eosinophilic granulomatosis and polyangii-
tis (EGPA/CSS), additional drugs, such as cyclophosphamide,
may be required. It is worth noting that corticosteroids can
induce apoptosis in eosinophils and their precursor cells and
also suppress synthesis of eosinophil-activating cytokines and
chemokines in T lymphocytes and other cells. In patients with
idiopathic HES and HES-L, glucocorticoids are also recom-
mended. However, side effects of long-term glucocorticoid
therapy may be a clinical challenge and may be dose-limiting.
Glucocorticosteroid-sparing agents may help in these cases.
Apart from conventional drugs, including hydroxyurea and
IFN-alpha, the anti-IL-5 antibody mepolizumab has been
shown to be a safe and effective corticosteroid-sparing agent
in these patients and is the only biologic approved for the
treatment of HES in the USA [125–129].
Most patients with primary (neoplastic) HE and HES are
not responding to corticosteroids or other anti-inflammatory
agents. In these patients, specific targeted drugs and/or (more)
intensive therapies are required to bring eosinophil counts and
HE under control [10, 11, 16–18, 107, 122–124, 128–132].
The classes and type of drugs are selected based on the under-
lying neoplasm, the molecular drivers detected, and the over-
all situation in each case. Therefore, it is essential to define the
molecular defects and the target expression profiles in clonal
cells and to establish the exact histomorphological diagnosis
and the extent of organ involvement and organ damage in
each case [8–19].
In many patients with eosinophil-rich neoplasms, a muta-
tion in PDGFRA or PDGFRB is detected [10, 11, 14–18]. The
most common genetic variant identified in such patients is
FIP1L1-PDGFRA. The respective fusion gene product,
FIP1L1-PDGFRA, is a well-established target of imatinib
and other PDGFR-directed TKI. Several other fusion gene
targets of imatinib have also been described in eosinophil-
rich BM neoplasms. Most fusion gene products involving
PDGFRA or PDGFRB receptors are sensitive to imatinib,
whereas oncogenic FGFR1 mutants are resistant [11, 16–18,
107, 128, 130–132].
In patients with chronic, eosinophil-rich, neoplasms
exhibiting FIP1L1-PDGFRA or other imatinib-sensitive
PDGFR variants, imatinib is regarded standard first-line
therapy [10, 11, 16–18, 105–109, 130–132]. Although
most patients show a long-lasting response to 100 mg
imatinib daily, a few patients require a dose of 200 or
400 mg per day. A very few patients develop resistant
disease, often in the context of rare secondary mutations
in FIP1L1-PDGFRA [107, 130–134]. For these patients
and for imatinib-intolerant cases, other PDGFR-targeting
drugs, such as sorafenib or midostaurin, should be con-
sidered provided that the disease still presents as a chronic
PDGFR-dependent neoplasm. Alternatively, these patients
are treated with hydoxyurea or more intensive therapy,
and the same holds true for patients in whom the disease
progresses into an acute resistant leukemia. In some of
these resistant patients, intensive chemotherapy and stem
cell transplantation have to be considered. Patients with
an advanced JAK2-mutated disease, including cases with
JAK2 V617F and those with PCM1-JAK2, JAK-targeting
drugs, such as ruxolitinib or fedratinib, may be consid-
ered. In patients with FGFR1-mutated chronic neoplasms
with HE, treatment options are limited. In some of these
patients, transient responses to midostaurin (in a ZNF198-
FGFR1+ disease) or ponatinib (in BCR-FGFR1+ leuke-
mia) have been described. However, in most patients, no
long-lasting effects are seen. For patients with FGFR-mu-
tated neoplasms, several FGFR-targeting drugs, such as
pemigatinib, have recently been developed and are cur-
rently tested in clinical trials. However, most of these
patients have drug-resistant disease and progress rapidly,
often in form of an aggressive stem cell disease or a
leukemia/lymphoma syndrome (8p11 syndrome). For
these patients, intensive poly-chemotherapy and allogene-
ic stem cell transplantation combined with specific
targeted drugs may be a reasonable approach to consider.
However, even such intensive therapies may not always
lead to long-term disease control or cure in patients with
the 8p11 syndrome.
Concluding remarks and future perspectives
Eosinophils are multifunctional effector cells of the im-
mune system that are involved in host defense, tissue re-
modeling, and tissue repair. Once activated, eosinophils
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may release toxic substances that support host defense
and may also cause tissue damage, especially in
hypereosinophilic states. HE may develop in the context
of various hematologic neoplasms and in certain reactive
states. In all these patients, it is important to (i) document
or exclude a related neoplastic or non-neoplastic disease,
and to (ii) document or exclude the presence of HE-
related organ damage which leads to the diagnosis of
HES. Clinically, the most frequent and most important
manifestations of HES are thromboembolic events.
Several immunological, serological, molecular, and cyto-
genetic markers are available to establish the nature of the
underlying condition and thus to define the variant of HE
and HES. Independent of the underlying condition, pa-
tients with established HES should be considered for early
therapeutic intervention. In those with secondary HES,
treatment of the underlying disease is usually effective.
In some of these patients, IL-5-targeting antibodies can
control HE. In myeloid neoplasms harboring mutated var-
iants of PDGFRA or PDGFRB, imatinib or other PDGFR-
targeting TKI are usually effective to control HE and to
avoid HES-related organ damage. Our increasing knowl-
edge about the etiology of HE, and the development of
more specific markers and therapeutic approaches, should
markedly improve diagnosis, management, and prognosis
of patients with eosinophil disorders.
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